Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial

Table 2 Mean SF-36 PCS and MCS scores at baseline and week 52 (ITT population)

	SF-36 PCS			SF-36 MCS
	TCZ-QW + Pred-26 N = 100	PBO + Pred-26 N = 50	PBO + Pred-52 N = 51	TCZ-QW + Pred-26 N = 100	PBO + Pred-26 N = 50	PBO + Pred-52 N = 51
Baseline	43.10 n = 97	42.65 n = 48	41.12 n = 49	42.77 n = 97	42.73 n = 48	40.45 n = 49
Week 52	47.75 n = 85	41.52 n = 43	41.24 n = 45	51.64 n = 85	49.36 n = 43	44.86 n = 45
LSM change from baseline to week 52	4.18*† n = 95	− 0.98 n = 47	− 0.40 n = 49	8.10†‡ n = 95	5.25† n = 47	1.89 n = 49

Data from patients who received prednisone escape therapy are included
ITT intent-to-treat, LSM least squares mean, MCID minimal clinically important difference, MCS Mental Component Summary, PBO placebo, PCS Physical Component Summary, QW every week, SF-36 36-Item Short-Form Health Survey, TCZ tocilizumab
*p < 0.001 vs PBO + Pred-26- and vs PBO + Pred-52
†Score ≥ MCID of 2.5 in patients with RA
‡p = 0.0727 vs PBO + 26-week taper and p < 0.001 vs PBO + 52-week taper

ISSN: 1478-6362